Article

Daily COVID-19 Supply Chain Updates

April 6, 2020
man washing hands at sink

Provista is committed to providing relevant and timely updates to ensure our members are best prepared for COVID-19.

Read the Vizient Update: COVID-19 - April 6, 2020 from our contracting partner Vizient.

Read the Vizient CEO Update: COVID-19 - April 3, 2020 to see what we and our contracting partner Vizient are doing for members.

Below you can find links for up to date information from suppliers, members, and industry experts to prepare your facility for COVID-19.

*To view the links, please login with your Provista portal username and password. If you do not have a login, register here.

For inquiries, please contact your Provista Account Executive.

updates and resources

The following resources provide the latest information regarding supply updates, product allocations, essential supplies on contract, clinical resources and pharmacy distribution and manufacturing status updates.

pharmacy updates

WEEK OF MARCH 23, 2020

MARKET TRENDS

This week marks demand driven signs of lower fill rates and tighter allocations on some products.

  • Chloroquine: All suppliers are on allocation at all distributors and Vizient is working with all suppliers to increase production. Bayer will donate 3 million tablets of Resochin (chloroquine phosphate) by the end of March.
  • Hydroxychloroquine: All suppliers are on allocation at all distributors and Vizient is working with all suppliers to increase production. Teva, Mylan and Novartis have additional suppliers projected to make over 100 million doses before the end of May.
  • Metered Dose Inhalers (MDI): Due to safety risk and infection control of using nebulizers for COVID-19 patients, MDIs of all types are beginning to be put on allocation at all distributors. Vizient is working with all MDI suppliers to increase production and the Vizient Center for Pharmacy Practice Excellence is finalizing a full report on best clinical practices and where and how nebulizers can be appropriated.
  • Actemra: Primarily used in rheumatoid arthritis, it has experienced a significant spike in purchasing since being identified as having off label use for treating COVID-19. Genentech has stated there are no supply issues and there is enough volume to cover the current patients. Genentech is going to work with the federal government on making additional product available. If Vizient members have issues ordering, please contact Genentech at (800) 551-2231 or go to www.gene.com/covid19.
  • Vizient is continuing to monitor products that are now being utilized by providers to manage the symptoms and impact of COVID-19 as well as essential medications that hospitals rely upon for the delivery of patient care. This includes daily monitoring of fill rates and/or allocation changes.
Advocacy update
  • Vizient provided pharmacy sourcing strategy recommendations to Vice President Pence on March 16, including the following: Prioritize approval of pending applications for “essential” medications subject to shortage. We are pleased to see that the FDA has taken action by quickly approving Bayer’s Resochin (chloroquine phosphate).
Supplier and clinical updates 
  • As a reminder, additional inventory held for the 11 key essential medications, such as Propofol and Enoxaparin, is available through Novaplus Enhanced Supply.
  • The Vizient supplier survey, requesting current API sources and manufacturing locations for all contracted Essential Medicines, will soon close. This information will be analyzed, aggregated and shared with members very soon.
  • As part of the Vizient RFP process, we are requiring contracted suppliers of essential medications to provide API origination and manufacturing locations.
  • The Vizient team also continues to work with all distributors on allocation of essential medications. We understand that distributors are starting to take additional precautionary measures around allocation.
  • The Center for Pharmacy Practice Excellence Team is reviewing key therapies and conducting a pharmacotherapy survey to members on the clinical management of COVID-19.
  • Vizient continues to maintain very close dialog with the US Food and Drug Administration (FDA), Centers for Disease Control (CDC), Strategic National Stockpile and the University of Utah Drug Information Center.

supplier customer letters

Read Awarded Supplier customer letters regarding personal protective equipment (PPE) allocations and supply status.

Non-pharmacy
Pharmacy

industry resources

Centers for Disease Control (CDC)

Emergency Operations Center: (770) 488-7100)

Food and Drug Administration (FDA)

Diagnostic Test Hotline- For test developers and labs who have questions about the EUA process or spot shortages of testing supplies. Contact our toll-free line 24 hours a day: 1-888-INFO-FDA, choose option *

Occupational Health and Safety Administration (OSHA)
The Joint Commission (JC)
U.S. Department of Health & Human Services (HHS)
Centers for Medicare and Medicaid Services (CMS)